A new study in juvenile zebra finches — a songbird species known for singing to attract mates — shows that mastering complex natural behaviors like singing depends on dopamine, a key signaling chemical that is lacking in the brains of people with Parkinson’s disease. The findings of this novel…
Vyalev (foscarbidopa and foslevodopa) demonstrated a favorable long-term safety and tolerability profile, along with sustained motor symptom control, in Parkinson’s disease patients who participated in the extension part of a Phase 3 trial (NCT03781167). Results from nearly two years of the extension study (NCT04379050) showed…
U.S. researchers have identified a novel way to block a protein known as DLK, or dual leucine-zipper kinase, that may offer a promising strategy to protect neurons from degeneration — which, the team notes, could pave the way for safer and more precise treatments for neurodegenerative conditions like Parkinson’s…
Arvinas has begun a Phase 1 clinical trial to test its investigational therapy ARV-102 in people with Parkinson’s disease, with Phase 1 data in healthy adults showing it was safe and worked as expected. ARV-102 is being developed for neurodegenerative conditions where the leucine-rich repeat kinase 2, or…
Spinal cord stimulation failed to improve walking ability despite multiple attempts in a small group of people with Parkinson’s disease who experienced freezing of gait — a symptom where the feet suddenly feel stuck and unable to move forward — according to the researchers running the study. The study…
Pretzel Therapeutics has launched a Phase 1 clinical trial to study PX578, a therapy designed to boost the function of mitochondria, the cell’s energy-producing powerhouses, and address conditions caused by faulty energy production. These include rare genetic conditions and neurodegenerative disorders like Parkinson’s and Alzheimer’s. The…
When used as a solo therapy, solengepras (CVN424) — an oral treatment being developed by Cerevance — was seen to lessen both functional and nonmotor symptoms in people with early, untreated Parkinson’s disease. That’s according to top-line results from the Phase 2 ASCEND trial (NCT06006247), which…
Nitrase Therapeutics’ NDC-0524, an antibody therapy for Parkinson’s disease, significantly reduced alpha-synuclein aggregation and spreading in mouse models of the disease, according to preclinical data released by the company. The antibody targets nitrated alpha-synuclein, a misfolded form of the protein that forms toxic clumps in dopaminergic neurons, the nerve cells…
The flamingo exercise — training to stand on one leg, as the bright-pink wading birds often do — was shown to improve balance and reduce the risk of falls among people with Parkinson’s disease in a Turkish study. Such balance training was found most effective when the exercise was…
Medications commonly used to treat conditions such as high blood pressure, high cholesterol, and pain may delay Parkinson’s disease onset, according to a U.S. study. Analyses found that anti-hypertensives such as adrenergic blockers, cholesterol-lowering statins, and non-steroidal anti-inflammatory drugs (NSAIDs) were strongly associated with later onset disease. In contrast,…
Get regular updates to your inbox.
